logo
Teen cannabis use increased after legalization in Canada, study finds

Teen cannabis use increased after legalization in Canada, study finds

Yahoo22-04-2025
If you or someone you know is struggling with mental health, help is available. Dial or text 988 or visit 988lifeline.org for free and confidential support.
Legalization of cannabis products may be linked to growing use among teens, a new study found.
Teen use of cannabis rose 26% in Canadian provinces that legalized the sale of edibles and extracts in October 2019, according to the study, which published Friday in the journal JAMA Network Open.
Edible use increased 43%, raising concerns about youth-friendly forms of the drug, such as cannabis chocolates, candies, sodas and desserts — the same products responsible for a growing number of child hospitalizations in the US.
Based on surveys of more than 106,000 students aged 12 to 17 years old, the study found use remained stable in Quebec, where the sale of these products was still banned.
Canada legalized dried cannabis use in October 2018, and all Canadian provinces except Quebec followed a year later by legalizing the sale of cannabis edibles and extracts.
While Canada's 2018 law prohibits the sale of cannabis to individuals under 18, the study suggests legalization could have made these products more accessible to teens and influenced their attitudes surrounding use.
Canadian laws require child-resistant, plain and clearly labeled packaging for cannabis edibles, but illicit products sold online and by unauthorized distributors often look like other snacks, according to the study.
'This finding is important in light of previous literature regarding potential long-term adverse health effects of cannabis use for adolescents,' said senior author Dr. Hai Nguyen, a professor in the School of Pharmacy at Memorial University of Newfoundland, in an email.
Teens using cannabis products regularly are at a greater risk for developing dependency disorders later in life, according to neuroscientist Joshua Gowin, who was not involved in the study.
'Some (studies) suggest that cannabis use during adolescence, especially heavy use, could alter brain development,' said Gowin, an assistant professor of radiology at the University of Colorado School of Medicine. 'If you start using earlier, it may be harder to change that trajectory later on.'
Cannabis use can affect parts of the brain that deal with attention, coordination, learning, decision-making and emotional regulation, according to the US Centers for Disease Control and Prevention.
Use at an early age has been linked to mental health issues such as depression, anxiety, and a heightened risk of developing longer-lasting mental health disorders, such as schizophrenia, in adulthood.
Despite these risks, the study found the students perceived less harm from occasional cannabis use because of its legalization.
Using both cannabis and alcohol at the same time, which studies show can lead to higher and more frequent consumption of both, was 28% more prevalent after legalization as well.
When it comes to social attitudes around drug use, causality is often complicated to prove, because laws can change in response to cultural changes as well, Gowin said. For this reason, other research methods beyond surveys can play an important role in understanding the effects of legalization for future policymaking decisions.
In the US, the relationship between adolescent use and legalization may be even more complex to study because of variations in state and local regulations, Gowin said.
Federally, cannabis is illegal, but 47 states have legalized it for medical uses and 24 states for adult recreational purposes. Each state has its own laws about marketing, packaging and distribution of these products.
Nguyen also noted his research only addresses short-term effects based on one point in time after legalization, so it's important to continuously study how use patterns evolve and reflect changes in the laws.
In the meantime, Nguyen recommended policymakers focus on striking the right balance between adult access and teen protection. Further enforcement may be needed to crack down on marketing and packaging that appeals to younger people, he noted, and local regulators can ensure cannabis distributors are located an appropriate distance away from schools.
'It is also essential to invest in public education campaigns that raise awareness about the risks of cannabis use among adolescents,' Nguyen said, adding that multimedia public health campaigns, school-based awareness efforts and parent-child communication are all important prevention strategies.
Parent-youth communication guides can help families have more informed conversations at home and navigate common misconceptions about edible use, Nguyen said.
'It's not about scaring people,' Gowin said. 'Honesty and truth can be at the forefront of the conversations and hopefully people can make up their own minds about what's the best thing for them, their families and their communities.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

First human case of West Nile virus acquired in Canada this year confirmed
First human case of West Nile virus acquired in Canada this year confirmed

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

First human case of West Nile virus acquired in Canada this year confirmed

TORONTO - The Public Health Agency of Canada says this year's first human case of West Nile virus acquired within the country has been confirmed in Toronto. The confirmation comes after Toronto Public Health said its first laboratory-confirmed case of the virus in 2025 is an adult resident of the city with no travel history. The virus is transmitted to humans through infected mosquitoes. PHAC's West Nile surveillance report says that as of July 12, two other Canadian residents were infected this year while travelling outside of the country. Its surveillance map shows West Nile detections in two mosquito pools in Ontario and one in Manitoba as of that date. Toronto Public Health says symptoms usually begin between two to 14 days after a mosquito bite and can include fever, headache, nausea, vomiting, body aches, skin rash, swollen lymph glands or a stiff neck. It says older adults and people with compromised immune systems are at higher risk of severe illness. People can prevent infection by avoiding mosquito bites — wear light-coloured long sleeves and long pants, use Health Canada-approved insect repellent, put tight-fitting screens on all windows and get rid of standing water in buckets, planters, pool covers and other containers to eliminate mosquito breeding grounds. This report by The Canadian Press was first published July 31, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma
Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma

Business Wire

time4 hours ago

  • Business Wire

Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma

OTTAWA, Ontario & YORK, England--(BUSINESS WIRE)--Genvira Biosciences Inc. ('Genvira'), a Canadian innovator in next-generation viral vectors, Labskin Limited ('Labskin'), a leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) are pleased to announce the launch of a collaborative project to develop novel immunotherapies for malignant melanoma. The collaboration is receiving advisory services and up to £1.2 million ($2.0 million) in funding through the Canada–UK Biomanufacturing of Biologics and Advanced Therapies program. UK participants are supported by Innovate UK, part of UK Research and Innovation (UKRI), while in Canada, support for the project is offered through the NRC Industrial Research Assistance Program (NRC IRAP) and the NRC Collaborative Science and Technology Innovation Program (NRC CSTIP). Malignant melanoma continues to be a serious global health concern, with an estimated 330,000 new cases and 60,000 deaths each year. This international partnership aims to address the unmet need by developing cutting-edge cancer vaccines and optimizing targeted antigen delivery systems. As part of the collaboration, Labskin will utilize its expertise in advanced disease modeling to develop a novel 3D human skin model of melanoma, enabling in vitro testing of vaccine candidates. Genvira will contribute its proprietary viral vector and gene delivery platforms, while the NRC will support the integration of mRNA technologies to engineer innovative, targeted immunotherapies tailored to melanoma. Dr. Nicola Kingswell, Scientific Director at Labskin Limited, stated: 'We're extremely grateful to Innovate UK for supporting this exciting project. It represents a step-change in the treatment of malignant melanoma, which will benefit many patients worldwide. This partnership will not only produce and validate new immunotherapies, but also establish a framework for developing future cancer therapeutics.' Dr. Jiahu Wang, President of Genvira Biosciences, added: 'We'd like to thank NRC IRAP for their support, and the NRC for their collaborative role. This partnership enables us to rapidly translate our viral vector technologies into clinical applications for melanoma and lays the groundwork for broader advances in cancer immunotherapy.' The project brings together unique and complementary strengths in 3D tissue engineering, gene and viral therapy, mRNA technology, and advanced biomanufacturing. In addition to therapeutic development, the consortium will focus on scalable production processes, quality control assays, and robust technologies to enable rapid response to future healthcare challenges. This initiative highlights the importance of international collaboration in driving innovation and accelerating the development of advanced biologics and therapies. About Labskin Limited Labskin Limited is a UK-based biotechnology company specializing in full-thickness human skin models for pharmaceutical, cosmetic, and clinical research. Its advanced 3D platforms offer realistic testing environments for evaluating treatments in vitro. To learn more: About Genvira Biosciences Inc. Genvira Bioscience is a Canadian biotechnology company focused on designing and developing viral vector platforms for use in gene therapies, cancer vaccines, and regenerative medicine. To learn more:

I Was Diagnosed With Bipolar I After Ignoring These Signs for a Year
I Was Diagnosed With Bipolar I After Ignoring These Signs for a Year

WebMD

time4 hours ago

  • WebMD

I Was Diagnosed With Bipolar I After Ignoring These Signs for a Year

Bipolar disorder is a mental health condition characterized by dramatic mood episodes that include mania or hypomania. These 'high' moods alternate with periods of depression. People who manage the condition can live fulfilling, happy lives. According to the Canadian Journal of Psychiatry, it takes on average six years for a person to be diagnosed with bipolar disorder. When the condition is undiagnosed, it can wreak havoc on a person's life. The mood episodes can become more severe the longer a person is untreated. Luckily, I received a diagnosis within one year of the symptoms starting, but that's probably because I developed more serious psychotic symptoms. Looking back, I realize that there were red flags that I ignored before my diagnosis. Hyperfixation on Goals About a year before I was diagnosed, I officially started my mental health marketing company. At this time, I started working upwards of 80 hours a week. I felt super motivated, adopted a 'hustle mindset,' and became hyper-focused on my goals. I considered this healthy ambition and didn't think much of it. However, looking back, I realize that this was an increase in goal-directed activity, which is a sign of bipolar disorder. Brain Fog In the year leading up to my diagnosis, I had pretty bad brain fog. I would forget what I was doing just five minutes prior. I knew this wasn't normal. I felt like something was wrong, and this feeling wouldn't go away. So I made an appointment with my primary care doctor. I described my brain fog to him. He dismissed this issue as being due to normal age-related memory changes. I wasn't quite satisfied with this answer. But I think it's what I wanted to hear. So I ignored my concerns and didn't bring the issues up to him again. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) doesn't list "brain fog" as a specific symptom of bipolar disorder. However, it turns out that memory and cognitive issues are common in bipolar disorder. Sleep Changes I started experiencing sleep changes about a year or so before my diagnosis. I would stay up very late, working well into the early morning hours. Sometimes, I wouldn't go to bed until close to dawn. At the time, I wasn't tracking my sleep. (Now I do). But I probably wasn't getting enough sleep. Because of the changes in my sleep patterns, I saw a sleep specialist. He diagnosed me with a delayed sleep-wake phase disorder, which is a circadian rhythm disorder. I've since learned that circadian rhythm disorders are common in people with bipolar disorder. Anxiety A couple of weeks before my first manic episode, I had what I would call 'anxious distress.' This went way beyond regular stress. I felt as though I couldn't handle or manage things. I worried that I was losing control. This was different from normal for me. I'd never had anxiety like this before. I was later diagnosed with an anxiety disorder as well. I learned that bipolar and anxiety disorders often co-occur. Paranoia I started to have paranoia right before I was diagnosed. Most people experience feelings of paranoia from time to time. So I brushed it off. However, paranoia is a sign of psychosis, which can occur with bipolar disorder. My Advice I would encourage anyone having similar issues to make an appointment with a licensed mental health professional. Advocate for yourself. Bipolar disorder is treatable with medications and therapy. Even if it isn't bipolar, it's important to find out what is going on.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store